<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63924">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117037</url>
  </required_header>
  <id_info>
    <org_study_id>2014-04</org_study_id>
    <nct_id>NCT02117037</nct_id>
  </id_info>
  <brief_title>Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes</brief_title>
  <official_title>Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study aimed to validate a new prognostic approach of endothelial progenitor
      cells  associated biomarkers in patients with acute coronary syndromes .  Recruitment is
      made prospectively by two centers of Inter -region South Mediterranean,
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>evaluate the value of circulating endothelial progenitor cells quantification in the initial phase of ACS in predicting the occurrence of a major cardiovascular event (ECVM ) at 1 year.</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>determine the technical characteristics (sensitivity and specificity) and predictive value of the number of PEC</measure>
    <time_frame>one day , one month , one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>determine the technical characteristics (sensitivity and specificity) and performance (technical and predictive) of chemokines / receptors expression  in the occurrence of ECVM</measure>
    <time_frame>one day, one month ,one year</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Determine the above performance in the subgroup of patients defined as incompletely revascularized (at least a residual stenosis &lt; 70%)</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Acute Coronary Syndromes</condition>
  <arm_group>
    <arm_group_label>study of PEC markers and chemokines/ chemokine recep</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>blood sample for dosage and study of PEC markers and chemokines/ chemokine receptors</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <arm_group_label>study of PEC markers and chemokines/ chemokine recep</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute coronary syndrome (ST + &lt; 12 hours and ST- high risk or intermediate risk
             ),which there is an indication of percutaneous coronary intervention.

        Exclusion Criteria:

          -  Cancer

          -  Chronic inflammatory disease

          -  Infectious disease

          -  Erythrocyte &lt;4 G/l

          -  Thrombopénia less than 100 000/mm3  ;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>laurent BONELLO, MD</last_name>
    <phone>33491965407</phone>
    <email>laurent.bonello@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent BONELLO, MD</last_name>
      <email>laurent.bonello@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent BONELLO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
